Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

Chiara Starvaggi Cucuzza, MD, Elisa Longinetti, PhD, Nicolas Ruffin, PhD, Björn Evertsson, MD, Ingrid Kockum, PhD, Maja Jagodic, PhD, Faiez Al Nimer, MD, PhD, Thomas Frisell, PhD, and Fredrik Piehl, MD, PhD

Neurol Neuroimmunol Neuroinflammm 2023;10:e200056. doi:10.1212/NXI.00000000000200056

Abstract

Background and Objectives
B cell–depleting therapies are highly effective in relapsing-remitting multiple sclerosis (RRMS) but are associated with increased infection risk and blunted humoral vaccination responses. Extension of dosing intervals may mitigate such negative effects, but its consequences on MS disease activity are yet to be ascertained. The objective of this study was to determine clinical and neuroradiologic disease activity, as well as B-cell repopulation dynamics, after implementation of extended rituximab dosing in RRMS.

Methods
We conducted a prospective observational study in a specialized-care, single-center setting, including patients with RRMS participating in the COMBAT-MS and MultipleMS observational drug trials, who had received at least 2 courses of rituximab (median follow-up 4.2 years, range 0.1–8.9 years). Using Cox regression, hazard ratios (HRs) of clinical relapse and/or contrast-enhancing lesions on MRI were calculated in relation to time since last dose of rituximab.

Results
A total of 3,904 dose intervals were accumulated in 718 patients and stratified into 4 intervals: <8, ≥8 to 12, ≥12 to 18, and ≥18 months. We identified 24 relapses of which 20 occurred within 8 months since previous infusion and 4 with intervals over 8 months. HRs for relapse when comparing ≥8 to 12, ≥12 to 18, and ≥18 months with <8 months since last dose were 0.28 (95% CI 0.04–2.10), 0.38 (95% CI 0.05–2.94), and 0.89 (95% CI 0.20–4.04), respectively, and thus nonsignificant. Neuroradiologic outcomes mirrored relapse rates. Dynamics of total B-cell reconstitution varied considerably, but median total B-cell counts reached lower level of normal after 12 months and median memory B-cell counts after 16 months.

Discussion
In this prospective cohort of rituximab-treated patients with RRMS exposed to extended dosing intervals, we could not detect a relation between clinical or neuroradiologic disease activity and time since last infusion. Total B- and memory B-cell repopulation kinetics varied considerably. These findings, relevant for assessing risk-mitigation strategies with anti-CD20 therapies in RRMS, suggest that relapse risk remains low with extended infusion intervals. Further studies are needed to investigate the relation between B-cell repopulation dynamics and adverse event risks associated with B-cell depletion.
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the CNS, affecting 2.8 million people worldwide.1 Most patients initially present with acute/subacute episodes of neurologic deficit, with variable degree of reversibility, followed by a period of clinical stability, thus classified as relapsing-remitting MS (RRMS). Accumulating evidence demonstrates that B cell–depleting therapies are associated with strong suppression of RRMS inflammatory disease activity.2–4 So far, 2 anti-CD20 monoclonal antibodies, ocrelizumab and ofatumumab, have been approved for use in RRMS in the United States and European Union. In addition, rituximab, an older chimeric monoclonal antibody approved for rheumatoid arthritis and other indications, is increasingly being used off-label in some countries, including Sweden. The safety profile of anti-CD20 therapies in RRMS comprises an increased infection risk,5 including worsened COVID-19 outcomes.6–8 Furthermore, anti-CD20s blunt humoral responses to vaccinations,9 including for SARS-CoV-2.10,11 Collectively, these data warrant studies exploring risk-mitigation strategies to ensure an optimized benefit-risk balance for patients with RRMS treated with anti-CD20s. So far, however, such efforts comprise relatively small-sized studies with limited dosing interval prolongation and short observation time.12,13 Larger real-world cohort studies with sufficiently long observation time to determine time to normalization of B-cell levels and possible relation to disease activity and risk of adverse events are thus lacking. Considering an emerging safety signal with rituximab infusions, it was not possible to attribute the occurrence of new or enlarged T2 lesions to a specific infusion interval; hence, data are presented for each participant according to the longest interval ever experienced.

The effect of dose interval extension was assessed by comparing relapse rates during <8, ≥8 to 12, ≥12 to 18, and ≥18 months since last infusion. Treatment interval was analyzed as a time-varying covariate. As a result, treatment intervals longer than 8 months were spilt in more than 1 category, where for example a 14 months interval since last rituximab infusion contributed data to the <8, ≥8 and ≥12 months’ time bands. The interval after the first rituximab infusion (or after the first 2 infusions if <90 days apart) was excluded from the analysis to avoid the effect of residual disease activity early after treatment start (eFigure 1, http://links.lww.com/NXI/A770).

The following were considered potential confounders: sex, age at infusion, EDSS at infusion, number of previous rituximab doses, number of clinical relapses in the year before rituximab start, number of brain MRI T2 lesions at rituximab start (categorized as 0, 1–9, 10–20, and >20), and previous DMTs, classified as none, moderately effective (injectables, dimethyl fumarate, teriflunomide, or daclizumab), highly effective (fingolimod, natalizumab, or ocrelizumab), and others (unspecified).

Methods

Study Population
The study population at the Academic Specialist Center (Stockholm, Sweden) included 718 patients with RRMS enrolled in either of 2 prospective observational drug trials, COMBAT-MS (n = 658) and MultipleMS (n = 60), who had been exposed to at least 2 doses of rituximab by September 1, 2021 (Figure 1A). The COMBAT-MS study included patients with RRMS initiating a first disease-modifying therapy (DMT) or doing a first DMT switch between January 1, 2011, and October 31, 2018. The MultipleMS study included newly diagnosed, treatment-naive patients with RRMS who initiated a first DMT between April 1, 2018, and September 28, 2020. Data regarding demographics, disease, and treatment history were extracted from the Swedish MS registry. Data on total B-cell count and percentage of B cells subpopulations were extracted from medical records from January 1, 2018, to September 1, 2021.

Standard Protocol Approvals, Registrations, and Patient Consents
COMBAT-MS, EudraCT: 2016-003587-39, Clinicaltrials.gov identifier: NCT03193866; MultipleMS, EudraCT: 2017-002634-24. Written informed consent was obtained from all study participants (Stockholm Regional Ethics Board, no. 2017/32-31/4 and 2017/1323-31).

Follow-up, Outcomes, and Covariates
Patients were followed annually with assessment of Expanded Disability Status Scale (EDSS), relapse history, MRI, and acute contacts when needed. The MRI protocol has been published previously and considers contrast administration for follow-up scans as optional in case of a stable patient, leaving the decision to the treating neurologist.14 COMBAT-MS SMSReg data have been validated against medical records for completeness, and both studies are continuously monitored for data completeness.15 The outcomes in the main analysis were clinical relapses and brain or spinal cord contrast-enhancing lesions (CELS). Because annual MRI scans were not synchronized with rituximab infusions, it was not possible to attribute the occurrence of new or enlarged T2 lesions to a specific infusion interval; hence, data are presented for each participant according to the longest interval ever experienced.
B-Cell Data
Total B-cell (CD3+CD19+) levels were assessed by flow cytometry before each rituximab infusion, as per clinical routine, at the Department of Clinical Immunology, Karolinska University Hospital. B memory cell (CD3+CD19+CD27+immunoglobulin D (IgD)-, CD27+-IgD+, and CD27−IgD−) percentages were determined in patients with detectable B cells and converted to absolute numbers using the extracted data. B-cell data were assessed in relation to time since last infusion (in months). In instances where multiple measurements had been performed in the same treatment interval, only the last assessment was included. B-cell samples were classified as depleted if below the detection level (10 cells/μL for total B and 0.05 cells/μL for total and CD27+IgD− memory B), partially repleted if above the detection limit, but below lower limit of normal (LLN, 80 cells/μL for total B, 15.2 cells/μL for total memory B, and 5.6 cells/μL for CD27+IgD− memory B), and completely repleted if equal or above LLN.

Statistical Analysis
Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and corresponding 95% CIs of clinical relapse or CELs in relation to rituximab dose intervals. Time since disease onset was the underlying time scale in all models; thus, HRs were compared across patients with the same disease duration. Study entry occurred at each rituximab infusion, with left truncation of follow-up time to avoid immortal time bias (i.e., we used the counting process approach, with a start and a stop defining each patient’s each interval). Every time-to-censoring/outcome after a rituximab dose was subsequently split in the aforementioned time bands (<8, ≥8 to 12, ≥12 to 18, and ≥18 months), and HRs were calculated for ≥8 to 12, ≥12 to 18, and ≥18 months since last dose, using <8 months as reference (for further details, see eMethods, http://links.lww.com/NXI/A770). A sandwich estimator was used to account for exposure of the same patient to multiple rituximab dosing intervals. Models were separately analyzed as crude and adjusted for confounders (listed above). Censoring events were a subsequent rituximab infusion, conversion to secondary progressive MS (SPMS), emigration, death, or September 1, 2021, whichever came first. In the main analysis, we did not include date of switch to a different DMT as a censoring event in keeping with the hypothesis of a long-lasting effect of B-cell depletion and to maximize sensitivity for relapses. However, DMT switch (33 patients out of 718; 4.6%) was considered an additional censoring event in a sensitivity analysis to restrict the analysis time to exclusive exposure to rituximab. Negative binomial regression models were used to calculate repletion rate ratios (RRs) for total B- and memory B-cell counts per microliter in relation to months since last rituximab infusion. Both total B/memory B-cell counts per microliter and months since last rituximab infusion were regarded as numerical, continuous variables in the regression model. Stratification of the regression model by sex, age, body mass index (BMI), disease duration, and number of previous rituximab doses was performed to uncover possible effect modifiers, with continuous variables transformed in binary variables taking the approximate median value as splitting point. With this approach, age was categorized as <40 and ≥40 years, BMI as <24 and ≥24 kg/m², disease duration as <8 and ≥8 years since disease onset, and number of previous rituximab doses as 1–3 or ≥4. Analyses were conducted with STATA/BE software, 17.0.
Data Availability
Deidentified or aggregated data will be shared with qualified investigators on reasonable request and pending a relevant data transfer agreement, in compliance to European legislation.

Results
Study Participants
We identified 718 unique patients with RRMS enrolled in either COMBAT-MS or MultipleMS studies who had been exposed to at least 2 courses of rituximab treatment, for a total of 4622 treatment episodes (Figure 1A and eFigure 2a, http://links.lww.com/NXI/A770). Patients were followed from each rituximab infusion until subsequent infusion, occurrence of clinical relapse or CELs, emigration (n = 1), death (n = 3), transition to SPMS (n = 19), or end of follow-up, whichever came first. After exclusion of the first treatment course, these individuals had accumulated 3,904 rituximab dose intervals, for a median follow-up of 4.2 years (interquartile range 2.7–5.6 years). The baseline characteristics of study participants are summarized in Table 1. The infusion-to-outcome/censoring intervals were distributed as follows: 2,577 intervals (66%) <8 months, 585 (15%) ≥8–12 months, 323 (8%) ≥12–18 months, and 419 (11%) ≥18 months. Importantly, 95% of patients (n = 683) underwent at least 1 interval extension (≥8 months), with 87% (n = 628) and 56% (n = 403) exposed to an interval of ≥12 months and ≥18 months, respectively. Of the remaining 35 participants, the main reasons for remaining on a <8 months treatment schedule were (1) censoring event before implementation of extension protocol, n = 16 (due to conversion to SPMS, n = 15, or death, n = 1); (2) receiving a second course of rituximab after January 1, 2021, consequently too early to have been exposed to dose interval extension; and (3) unspecified reasons (n = 9), likely involving personal preferences of the treating neurologist and/or the patient.

Clinical Relapse Occurrence and Relation With Time Since Last Rituximab Infusion
During follow-up, a total of 24 relapses were recorded (eFigure 2b, http://links.lww.com/NXI/A770) with the annualized relapse rate dropping from a mean of 0.49 (95% CI 0.44–0.54) in the year

### Table 1  Cohort Demographic and Clinical Characteristics

| Overall (n = 718) |
|-------------------|
| **No. of females (%)** | 511 (71) |
| **Age at onset, median (Q1–Q3)** | 29 (24–36) |
| **Age at diagnosis, median (Q1–Q3)** | 32 (26–39) |
| **Age at RTX start, median (Q1–Q3)** | 37 (30–45) |
| **Disease duration at RTX start (y), median (Q1–Q3)** | 5.5 (1.9–10.8) |
| **ARR in the year before RTX start, mean (SD)** | 0.49 (0.67) |
| **EDSS at RTX start, median (Q1–Q3)** | 2 (1–2.5) |

| No. of brain T2 lesions at RTX start, no. of patients (%) |
|----------------------------------------------------------|
| 0 lesions | 7 (1) |
| 1–9 lesions | 141 (20) |
| 10–20 lesions | 196 (28) |
| >20 lesions | 359 (51) |

| Class of previous DMT, no. of patients (%) |
|-------------------------------------------|
| None | 258 (36) |
| Moderately effective<sup>a</sup> | 273 (38) |
| Highly effective<sup>b</sup> | 151 (21) |
| Others<sup>c</sup> | 36 (5) |

| No. of RTX doses, median (Q1–Q3) | 6 (4–8) |
| Duration of follow-up (y), median (Q1–Q3) | 4.2 (2.7–5.6) |

Abbreviations: ARR = annualized relapse rate; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; Q1 = first quartile; Q3 = third quartile; RTX = rituximab.

<sup>a</sup>Injectables, teriflunomide, dimethyl fumarate, and daclizumab.

<sup>b</sup>Fingolimod, natalizumab, and ocrelizumab.

<sup>c</sup>Unspecified or study drug.
before rituximab start to 0.03 (95% CI 0.02–0.05) in the first treatment year and ≤0.01 onward, up to 10 years of follow-up (eFigure 2c, http://links.lww.com/NXI/A770).

We subsequently determined whether longer time since last rituximab infusion was associated with increased risk of a clinical relapse. HRs compared with <8 months since last infusion were 0.28 (95% CI 0.04–2.10), 0.38 (95% CI 0.05–2.94), and 0.89 (95% CI 0.20–4.04) for ≥8 to 12, ≥12 to 18, and ≥18 months, respectively (Table 2). Adjustment for potential confounders did not substantially divert from the crude model. Adjusted HRs for ≥8 to 12, ≥12 to 18, and ≥18 months compared with <8 months since last infusion were 0.30 (95% CI 0.04–2.32), 0.42 (95% CI 0.05–3.23), and 0.85 (95% CI 0.18–3.92), respectively.

When considering date of switch to a different DMT as adjunctive censoring parameter, 3 relapses were censored, leaving a total of 21 clinical relapses. In this setting, adjusted HRs compared with <8 months resulted in 0.32 (95% CI 0.04–2.38) for ≥8–12 months and 0.68 (95% CI 0.07–6.6) for >18 months since last rituximab dose, whereas HR for ≥12–18 months could not be calculated due to the absence of events (Table 2). Overall, these point estimates suggest a similar or lower risk of relapse with transition from a regular to an extended dosing interval regimen.

### Inclusion of Contrast-Enhancing Lesions as Outcome

Neuroradiologic assessments conducted with administration of contrast agent (1,370 brain or spinal cord MRI scans out of 3,075 total scans, 44.6%, resulting in 548 patients with at least 1 follow-up scan with contrast administration) were evaluated. Among these, 11 scans revealed CEL events, 4 of which were performed in the same treatment interval of a registered clinical relapse. When considering both relapse and/or CELs, 31 disease activity events were recorded, with HRs of 0.24 (95% CI 0.03–1.77), 0.66 (95% CI 0.15–2.93), and 0.72 (95% CI 0.17–3.08) for ≥8 to 12, ≥12 to 18, and ≥18 months, respectively, compared with <8 months since last dose, respectively (Table 2).

Overall, the risk of an adverse efficacy outcome did not noticeably change up to 3 years after rituximab infusion, with an

### Table 2

| Clinical relapses | No. events | Person-years | Incidence rate | Cox model HR (95% CI)* |
|-------------------|------------|--------------|----------------|------------------------|
|                   |            |              |                | **Crude**              | **Adjusted**     |
| <8 months         | 20         | 2,119.6      | 0.009          | 0.28 (0.04–2.10)       | 0.30 (0.04–2.32) |
| ≥8–12 months      | 1          | 326.4        | 0.003          | 0.38 (0.05–2.94)       | 0.42 (0.05–3.23) |
| ≥12–18 months     | 1          | 262.3        | 0.003          | 0.89 (0.20–4.04)       | 0.85 (0.18–3.92) |
| ≥18 months        | 2          | 256.3        | 0.008          |                        |                 |

| Clinical relapses and/or CELs | No. events | Person-years | Incidence rate | Cox model HR (95% CI)* |
|-------------------------------|------------|--------------|----------------|------------------------|
|                               |            |              |                | **Crude**              | **Adjusted**     |
| <8 months                     | 26         | 2,117.4      | 0.012          |                        |                 |
| ≥8–12 months                  | 1          | 325.8        | 0.003          | 0.24 (0.03–1.77)       | 0.26 (0.03–1.96) |
| ≥12–18 months                 | 2          | 261.3        | 0.008          | 0.66 (0.15–2.93)       | 0.72 (0.17–3.08) |
| ≥18 months                    | 2          | 249.7        | 0.008          | 0.72 (0.16–3.35)       | 0.68 (0.14–3.24) |

| Clinical relapses DMT switch included in censoring | No. events | Person-years | Incidence rate | Cox model HR (95% CI)* |
|---------------------------------------------------|------------|--------------|----------------|------------------------|
|                                                   |            |              |                | **Crude**              | **Adjusted**     |
| <8 months                                        | 19         | 2,105.3      | 0.009          |                        |                 |
| ≥8–12 months                                     | 1          | 319.9        | 0.003          | 0.30 (0.04–2.26)       | 0.32 (0.04–2.38) |
| ≥12–18 months                                    | 0          | 250.7        | 0              | n/a                    | n/a              |
| ≥18 months                                       | 1          | 207.6        | 0.005          | 0.65 (0.08–5.21)       | 0.68 (0.07–6.60) |

Abbreviations: CEL = contrast-enhancing lesion; HR = hazard ratio.

*Time since disease onset as underlying time scale of all models.

+ Adjusted for sex, age at infusion, Expanded Disability Status Scale at infusion, previous disease-modifying therapies, number of brain MRI T2 lesions at rituximab start, annualized relapse rate in the year before rituximab start, and number of previous rituximab doses.
event-free survival rate of 0.98 (95% CI 0.97–0.99) (Figure 2A). In the same manner, the incidence rate for relapse and/or CELs remained stable across the 4 time bands (Table 2 and Figure 2B).

**New or Enlarging T2 Lesions on MRI Scans**

Forty-eight MRI scans in 44 patients (6.9% of 636 patients with valid follow-up and reference MRI scans) displayed new or enlarging T2 lesions. As yearly scans were not synchronized with rituximab infusions, the time period covered between follow-up and reference MRI scans did not match a specific treatment interval, so data are reported per individual instead of per dosing interval, with stratification for the longest treatment interval ever experienced when increase in T2 lesion burden was recorded. With this approach, 25 patients were in the <8 months group (out of 90 patients in this group, 27.8%), whereas 7 (out of 144, 4.8%), 4 (out of 242, 1.7%), and 8 (out of 160, 5%) were in the ≥8 to 12, ≥12 to 18, and ≥18 months groups, respectively.

**Total B-Cell Repopulation Kinetics**

B-cell data were available only after January 1, 2018, resulting in 1,744 data points for a total of 2,208 infusions after this date in 648 patients (79% of the infusions; 90% of the patient cohort). The median of total B-cell counts reached detectable levels 6 months since last infusion and the LLN after 12 months (Figure 3A). However, a considerable degree of variability of total B-cell levels was observed, with variance increasing over time since last infusion and a small proportion of subjects (3.4%) remaining completely depleted even with the longest dosing intervals. When considering the same time bands used in the main analysis, we found that 63.9% of samples remained depleted in the <8 months group. In contrast, the majority of samples were partially or completely repleted in the extended-interval groups. The 2 categories combined accounted for 87.1%, 97.9%, and 96.6% of the samples in the ≥8 to 12, ≥12 to 18, and ≥18 months groups, respectively (Figure 3B). Negative binomial regression confirmed positive association between B-cell levels and months since last infusion, with a repletion RR of 1.17 (95% CI 1.14–1.19, p < 0.0001). In other words, the model predicted an increase in B-cell counts of 17% every month in the analyzed data set. When stratifying according to age, sex, BMI, disease duration, or number of previous rituximab doses, we did not observe any significant effect modification by sex, age, and BMI, whereas longer disease duration and higher number of previous rituximab doses were associated with a slower rate of B cell repopulation, as expressed by the RR (interaction coefficients 0.94, 95% CI 0.9–0.98 and 0.9, 95% CI 0.86–0.95 for disease duration and number of previous doses, respectively). The stratified RRs were 1.21 (95% CI 1.18–1.25) and 1.14 (95% CI 1.12–1.16) for disease duration <8 or ≥8 years, respectively, and 1.24 (95% CI 1.19–1.30) and 1.12 (95% CI 1.10–1.15) for B-cell repopulating after infusions preceded by 1–3 or ≥4 rituximab doses, respectively (Figure 3, C and D).

**Memory B-Cell Repopulation Kinetics**

Memory B-cell data were available only for samples with detectable B cells. In this subgroup of 1,157 samples, 580 samples (46%) also included B-cell subpopulation analysis, for a total of 489 patients. Compared with total B-cell levels, memory B cells showed a slower repopulation kinetic: the median of memory B-cell counts, categorized in 1-month time bands, was steadily above the limit of detection but reached LLN only after 16 months (Figure 4A). Thus, memory B cells were partially repleted in the majority of samples in the first 2 time bands (79.7% and 59.5% for the <8 and ≥8–12 months,
respectively), whereas most samples (60.8%) were normalized after 18 months since last infusion (Figure 4B). Accordingly, when applying a negative binomial regression model, the repletion rate ratio was 1.03 (95% CI 1.02–1.04, Figure 4C). No effect modification was observed stratifying samples according to age, sex, BMI, disease duration, or number of previous rituximab doses (Figure 4D). When considering separately the 3 subsets composing memory B cells (CD27+IgD−, CD27+IgD+ or double positive, DP, and CD27−IgD− or double negative, DN), we noted different repopulation kinetics, with LLN reached in 12 and 7 months for DP and DN subsets, respectively (Figure 5A and B), whereas median levels of CD27+IgD− memory subpopulation persistently remained below LLN for up to 24 months (Figure 5C). As a result, this subset was only partially repleted in the majority of samples up to 24 months since last rituximab infusion: 87.5%, 84%, 77%, and 66.9% partially repleted samples for <8, ≥8 to 12, ≥12 to 18, and ≥18 months, respectively (Figure 5D).

**Discussion**

We here related inflammatory disease activity to time since last rituximab infusion in a large cohort of patients with RRMS exposed to dose interval extension with long prospective follow-up. Alike the ocrelizumab label, the Swedish MS Society recommends rituximab dosing (500 mg) every 6 months. Because of an emerging signal for increased infection rate over time,5 from October 2018, the Academic Specialist Center changed guidelines to recommend dose extension to 12 months after the fifth infusion for patients with stable disease. With the start of the COVID-19 pandemic in March 2020, infusion intervals were further extended to 12–24 months or more from the second infusion regardless of treatment duration, a decision also influenced by accumulating evidence suggesting an adverse effect on COVID-19 outcomes.6,7

We previously reported the absence of rebound disease activity in patients with RRMS who, for various reasons, had
stopped rituximab for more than 12 months. Similar results were reported for patients with RRMS exposed to low dose (<1000 mg yearly) or stopping treatment in another Swedish study. Furthermore, based on data from the phase II trial of ocrelizumab, which included a safety follow-up of about 12 months without treatment, it has been suggested that treatment intervals could be extended well beyond the regular 6-month interval. More recently, a retrospective observational study did not detect signs of disease activity rebound with extension of ocrelizumab intervals by 4 weeks or more. Finally, a Dutch prospective study implemented a personalized dosing interval of ocrelizumab based on B cell counts. In this study B-cell levels were assessed monthly after 6 months from the last infusion with retreatment with counts ≥10 cells/μL, which occurred at a median of 34 weeks since last infusion. However, all these studies were relatively small and had considerably shorter follow-up periods than included here, with a median structured prospective follow-up of 4.2 years (interquartile range 2.7–5.6 years).

Of interest, we could not detect an increased risk of clinical relapses and/or CELs for any of time bands analyzed, i.e., ≥8 to 12, ≥12 to 18, and ≥18 months, with point estimates of relapse risk remaining remarkably stable. Although the power to detect a difference was limited due to the limited number of relapse/CEL events, our observations suggest that both relapse risk and neuroradiologic disease activity remain low well beyond regular infusion intervals. The fact that HRs with extended dosing intervals in all cases were below 1 compared with the regular interval is reassuring, but likely can be influenced by overall treatment duration and a small number of subjects switching treatment or being held on shorter infusion intervals. It is important to note, however, that a substantial enrichment of stable patients in the longer time bands is unlikely given the prospective study design and the high proportion of participants being exposed to extended intervals. Taken together, these results are valuable for designing further, sufficiently powered confirmatory studies, but meanwhile provide
preliminary results indicating a viable approach for improving the benefit-risk balance with B cell-depleting DMTs. This is especially relevant in context of increased susceptibility to infections, lowered immunoglobulin levels, scheduling of vaccinations, or planning of pregnancy.\textsuperscript{5,10,19,20}

The striking efficacy of anti-CD20 therapies underscores the role of B cells in MS disease pathogenesis. Experiences across a wide spectrum of autoimmune conditions indicate numerous ways by which B cells can contribute to disease, which also depends on the type of disease process.\textsuperscript{21} In MS, B cells have been shown to produce cytokines with a presumed role in supporting CNS inflammation, with supporting functional data obtained in experimental autoimmune encephalitis, an animal model of MS.\textsuperscript{22,23} Notably, however, antigen-specific memory B-cell clones have also been shown to activate memory T cells with encephalitogenic features in subjects with RRMS ex vivo.\textsuperscript{24} The possible implication of this observation is that disease-driving cells mainly belong to the memory B-cell subtype, alike what has been suggested for neuromyelitis optica, where monitoring of memory B-cell subset has been suggested to be useful to determine anti-CD20 infusion intervals.\textsuperscript{25,26} However, it is important to acknowledge that clinical effectiveness of extended dosing intervals cannot readily be extrapolated due to different pathomechanisms, whereas it is more likely that B-cell repopulation kinetics will be more similar across the 2 conditions. However, in spite of increasing use of anti-CD20 therapies in MS, there is only limited information on the kinetics of B-cell repopulation after depletion and if there is any relation with return of disease activity. Insights regarding different memory B-cell subsets are also lacking. To this end, we analyzed total B-cell and memory B-cell counts determined in clinical routine for our cohort. Although limited by a certain irregularity of assessments in this real-world setting, our data, nonetheless, demonstrate a considerable variability in reconstitution kinetics of total B-cell numbers, where median counts were normalized after 12 months, whereas memory B cells remained below LLN for up 16 months since last dose. In the prediction model we used, based on negative binomial regression, total B-cell counts increased by 17% every month, with disease duration and number of previous rituximab doses negatively affecting repopulation rates, although results should be interpreted with some caution due to the variability in timing of sampling. Regarding memory B cells, the repletion rate was much slower, with a monthly increase  

![Figure 5](image)

(A–C) Box plot showing distributions of the 3 subsets of memory B cell: CD27\(^+\)IgD\(^−\) (A), CD27\(^+\)IgD\(^+\) or double positive (DP, B), and CD27\(^−\)IgD\(^−\) or double negative (DN, C). Samples were grouped into 1-month time intervals since last rituximab infusion. Continuous red line: memory B-cell detection limit (0.05 cells/\(\mu\)L for all subsets); dashed black line: lower limit of normal (5.6 cells/\(\mu\)L for CD27\(^+\)IgD\(^−\) cells, 3.44 cells/\(\mu\)L for DP cells and 1.92 cells/\(\mu\)L for DN cells). (D) Total number of observations (y axis) with relative frequencies (bar labels) of depleted (<0.05 cells/\(\mu\)L), partially repleted (≥0.05–5.6 cells/\(\mu\)L), and completely repleted (≥5.6 cells/\(\mu\)L) levels of CD27\(^+\)IgD\(^−\) memory B cells at <8 months, ≥8 to 12, ≥12 to 18, and ≥18 months since last rituximab infusion.
of only 3%. When considering different memory B-cell subsets, CD27−IgD− were the first to repopulate, followed by CD27+IgD+, whereas median levels of CD27+IgD− remained consistently below LLN up to 24 months since last infusion. Overall, these results might hint at different roles of memory B-cell subsets in RRMS pathogenesis. The low number of adverse efficacy events coupled with lack of systematic determination of B cells at occurrence of clinical or radiologic activity meant that a comparison between non-active and active patients could not be performed. However, it is evident that a strong signal for return of inflammatory disease activity with repletion of B cells, including of the memory subtype, is lacking.

Apart from previously mentioned limitations relating to the real-world nature of this study, including incomplete data coverage and variability in the structure of data collection, this study also did not include volumetric MRI data or soluble biomarkers such as neurofilament light chain concentrations. Thus, we cannot exclude that dose interval extension negatively affects disease processes not reflected by relapses or accrual of focal MRI lesions, and studies exploring the effect of extended B cell–depleting treatment schedules on the progressive aspects of MS are therefore warranted.

In summary, our findings suggest that anti-CD20 dose interval extension could be considered in patients with RRMS with stable disease without incurring risk of return of inflammatory disease activity in the short to medium term, especially in case of treatment-related adverse events or when planning pregnancy. Further studies are needed to determine whether dose interval extension is also associated with a lowered risk of infection, while it has been shown that systemic determination of B cells at occurrence of clinical or radiologic activity meant that a comparison between non-active and active patients could not be performed. However, it is evident that a strong signal for return of inflammatory disease activity with repletion of B cells, including of the memory subtype, is lacking.

**Acknowledgment**

The authors thank all the patients participating in the COMBAT-MS and the MultipleMS studies and Simon Englund, BSc, and Tommaso Piehl for their help with data collection.

**Study Funding**

This work was funded by the Patient-Centered Outcomes Research Institute (PCORI) Award (Combat-MS, MS-1511-33196), Swedish MRC grant no. 2020-02700, the European Union’s Horizon 2020 Research and Innovation Programme (MultipleMS, EU RIA 733161), the Knut and Alice Wallenberg Foundation, the Swedish Research Council for Health, Working Life, and Welfare (postdoc Grant No: 2020-0115 to E.L.), and the Swedish Brain Foundation.

**Disclosure**

F. Piehl has received research grants from Merck KGaA and UCB and fees for serving on DMC in clinical trials with Chugai, Lundbeck, and Roche. C. Starvaggi Cucuzza has received a travel grant from Sanofi Genzyme. B. Evertsson has received travel support from Roche. The remaining authors declare no competing interests. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation May 10, 2022. Accepted in final form September 16, 2022. Submitted and externally peer reviewed. The handling editor was Friedemann Paul, MD.

---

**Appendix**

**Authors**

| Name                        | Location                                                                 | Contribution                                                                                     |
|-----------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Chiara Starvaggi Cucuzza, MD| Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data |
| Elisa Longinetti, PhD       | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Nicolas Ruffin, PhD         | Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Björn Evertsson, MD         | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Ingrid Kockum, PhD          | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Maja Jagodic, PhD           | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data |
| Faiez Al Nimer, MD, PhD     | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and study concept or design |

---

**Neurology: Neuroimmunology & Neuroinflammation**

| Name Location Contribution                                                                 |
|------------------------------------------------------------------------------------------------|
| Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data |

---

**Disclosure**

F. Piehl has received research grants from Merck KGaA and UCB and fees for serving on DMC in clinical trials with Chugai, Lundbeck, and Roche. C. Starvaggi Cucuzza has received a travel grant from Sanofi Genzyme. B. Evertsson has received travel support from Roche. The remaining authors declare no competing interests. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation May 10, 2022. Accepted in final form September 16, 2022. Submitted and externally peer reviewed. The handling editor was Friedemann Paul, MD.

---

**Appendix**

**Authors**

| Name                        | Location                                                                 | Contribution                                                                                     |
|-----------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Chiara Starvaggi Cucuzza, MD| Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data |
| Elisa Longinetti, PhD       | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Nicolas Ruffin, PhD         | Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Björn Evertsson, MD         | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Ingrid Kockum, PhD          | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data |
| Maja Jagodic, PhD           | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data |
| Faiez Al Nimer, MD, PhD     | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Center for Neurology, Academic Specialist Center, Stockholm, Sweden; | Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and study concept or design |

---

**Disclosure**

F. Piehl has received research grants from Merck KGaA and UCB and fees for serving on DMC in clinical trials with Chugai, Lundbeck, and Roche. C. Starvaggi Cucuzza has received a travel grant from Sanofi Genzyme. B. Evertsson has received travel support from Roche. The remaining authors declare no competing interests. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation May 10, 2022. Accepted in final form September 16, 2022. Submitted and externally peer reviewed. The handling editor was Friedemann Paul, MD.
### References

1. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler. 2020;26(14):1816-1821. doi: 10.1177/1352458520970841.

2. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. doi: 10.1056/NEJMoa0706383.

3. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing-remitting multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi: 10.1056/NEJMo1601277.

4. Hauser SL, Bar-Or A, Cohen JA, et al. Oflutumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-557. doi: 10.1056/NEJMo1917246.

5. Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.

6. Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753.

7. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a north American registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699-708. doi: 10.1001/jamaneurol.2021.0688.

8. Schiavetti I, Ponzano M, Signori A, Bovis F, Carmisciano L, Sormani MP. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD20 therapies: a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;57:103358. doi: 10.1016/j.msard.2021.103358.

9. Asplund Högelin K, Pin E, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience. 2021;24(9):103078. doi: 10.1016/j.isci.2021.103078.

10. Apostolides SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2.

11. Rolles L, Paveltízk M, Pleiner S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1035. doi: 10.1212/NXI.0000000000001035.

12. van Lierop ZY, Toorep AA, van Ballegooij WJ, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. 2021;27(11):1990-2001. doi: 10.1177/13524585211028833.

13. Vågberg M, Axelsson M, Birgander R, et al. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurol Scand. 2017;135(1):17-24. doi: 10.1111/anm.12667.

14. Alping P, Pleiner S, Langer-Gould A, Frisell T; COMBAT-MS Study Group. Validation of the Swedish multiple sclerosis register: further improving a resource for pharmacoepidemiological evaluations. Epidemiology. 2019;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

15. Juto A, Fink K, Al Nimer F, Pleiner S. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis: no evidence of rebound disease activity. Mult Scler Relat Disord. 2020;37:101468. doi: 10.1016/j.msard.2019.101468.

16. Boremalm M, Sundström P, Salter J. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. J Neurol. 2021;268(6):2161-2168. doi: 10.1007/s00415-021-10399-8.

17. Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102279. doi: 10.1016/j.msard.2020.102279.

18. Voller BL, Wallach AJ, Corbový JR, Dubovskova K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020;7(9):1477-1487. doi: 10.1002/acn3.51136.

19. Razaz N, Pleiner S, Frisell T, Langer-Gould AM, McKay KA, Fink K. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020;11(6):7. doi: 10.1212/NXI.0000000000000903.

20. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020-00092-2.

21. Farr TA, Shen P, Brown S, et al. Cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5):1001-1010. doi: 10.1084/jem.20111675.

22. Li R, Rezak A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166. doi: 10.1126/scitranslmed.aab4176.

23. Jelic I, Al Nimer F, Wang J, et al. Memory B cells activate brain-homing, autoreactive CD4. Cell. 2018;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011.

24. Trewin BP, Adelstein S, Spins JM, et al. Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord. 2020;43:102175. doi: 10.1016/j.msard.2020.102175.

25. Novi G, Bovis F, Fabbrè S, et al. Tailoring B cell depletion therapy in MS according to clinical coepidemiologic evaluations. Mult Scler. 2020;26(3):101468. doi: 10.1177/1352458520102275.

26. Asplund Högelin K, Ruffin N, Pin E, et al. B cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients. Eur J Neurol. 2022;29(11):3317-3328. doi: 10.1111/ejn.15492.
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
Chiara Starvaggi Cucuzza, Elisa Longinetti, Nicolas Ruffin, et al.

*Neurol Neuroimmunol Neuroinflamm* 2023;10;
DOI 10.1212/NXI.0000000000200056

This information is current as of November 21, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/10/1/e200056.full.html

References
This article cites 27 articles, 5 of which you can access for free at:
http://nn.neurology.org/content/10/1/e200056.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

_Neurol Neuroimmunol Neuroinflamm_ is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.